Haemonetics Corp. Stock
€46.00
Your prediction
Haemonetics Corp. Stock
Pros and Cons of Haemonetics Corp. in the next few years
Pros
Cons
Performance of Haemonetics Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Haemonetics Corp. | 3.600% | -3.361% | -6.883% | - | -32.847% | - | - |
| Bio-Rad Labs Inc. A | -4.350% | -6.165% | -13.894% | -3.721% | -19.736% | -37.987% | -57.927% |
| CONMED Corp. | 3.360% | -4.487% | -4.487% | -41.569% | -14.857% | -73.153% | -74.310% |
| Glaukos Corp | -0.860% | 0.000% | 15.152% | 44.304% | 18.135% | 115.094% | 83.871% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Haemonetics Corporation (HAE) from the Healthcare Equipment and Supplies industry have shown considerable growth in their financials over the past few years. At first glance, the company's financial performance seems to be on an upward trajectory, demonstrating a consistent increase in total assets, revenue, and net income.
Rising total assets: Haemonetics' total assets have grown from $1.267 billion in 2020 to $1.879 billion in 2022, which signifies approximately a 48% increase over the span of two years. The growth of total assets is a positive indication of the company's financial health and suggests an expanding business.
Steady growth in net income: The company's net income has grown consistently over the years, from $76.5 million in 2020 to $43.4 million in 2022. This growth is indicative of a healthier profit margin and effective cost management by the company.
Comments
News
Haemonetics Q4 Earnings Call Highlights
Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
Invenomic Capital Management fully exited its position in Haemonetics Corporation (NYSE:HAE), according to a February 17, 2026, SEC filing, selling 498,317 shares previously worth $24.29 million.
